Introduction {#ajum00171-sec-0001}
============

Choriocarcinoma is a rare, aggressive subtype of gestational trophoblastic neoplasia that affects an estimated 1 in 24,000[^1^](#ajum00171-bib-0001){ref-type="ref"} to 1 in 40,000[^2^](#ajum00171-bib-0002){ref-type="ref"} ^,^ [^3^](#ajum00171-bib-0003){ref-type="ref"} pregnancies in the United States. The disease has a propensity for metastasis to the lungs, brain, liver, vagina, and pelvis and arises from hydatidiform moles in about 50% of cases, although choriocarcinoma can be associated with any type of pregnancy.[^2^](#ajum00171-bib-0002){ref-type="ref"} The diagnosis of metastatic choriocarcinoma in the setting of a viable intrauterine pregnancy is exceedingly rare with less than 50 cases reported in the literature[^4^](#ajum00171-bib-0004){ref-type="ref"} ^--^ [^6^](#ajum00171-bib-0006){ref-type="ref"} and carries significantly increased morbidity and mortality for mother and neonate.[^7^](#ajum00171-bib-0007){ref-type="ref"} Diagnosis is typically based on and abnormal hCG level as well as presence of metastatic disease.[^8^](#ajum00171-bib-0008){ref-type="ref"} Histopathologic diagnosis is not considered mandatory for initiation of treatment.[^9^](#ajum00171-bib-0009){ref-type="ref"} ^,^ [^10^](#ajum00171-bib-0010){ref-type="ref"} Treatment during pregnancy is acceptable; however, the optimal management of these pregnancies and timing of delivery must be indivisualsed.[^11^](#ajum00171-bib-0011){ref-type="ref"}

Choriocarcinoma is characterised by invasion of throphoblastic tissue into the uterine musculature and maternal vascular spaces with hemorrhage and necrosis; this allows for fetal cells to cross the placental barrier resulting in the potential for large feto‐maternal hemorrhage.[^12^](#ajum00171-bib-0012){ref-type="ref"} The diagnosis of feto‐maternal hemorrhage is made either by intrauterine fetal demise associated with hydrops fetalis, abnormal monitoring, or as neonatal anemia.[^13^](#ajum00171-bib-0013){ref-type="ref"} The diagnosis of choriocarcinoma is often not made until postpartum based on pathology or presentation of maternal disease.[^14^](#ajum00171-bib-0014){ref-type="ref"} Rarely is the diagnosis of choriocarcinoma made antepartum without associated fetal compromise or disease.

Measured Doppler peak systolic velocity (PSV) of the middle cerebral artery (MCA) is an established tool for the diagnosis and management of fetal anemia.[^15^](#ajum00171-bib-0015){ref-type="ref"} The technique involves measuring the peak velocity of blood in the MCA and comparing it to established normal values for peak velocity. Fetuses with values greater than 1.50 multiples of the median (MoM) indicate significant anemia.[^16^](#ajum00171-bib-0016){ref-type="ref"} First used in the diagnosis of fetal anemia secondary to alloimmunisation, MCA‐PSV has also been used in the evaluation of anemia resulting from feto‐maternal hemorrhage.[^17^](#ajum00171-bib-0017){ref-type="ref"}

We present a case of metastatic choriocarcinoma with a concurrent viable fetus diagnosed at 34 weeks gestational age in which the use of MCA‐PSV Dopplers assisted in optimising the timing of delivery with positive maternal and neonatal outcomes.

Case {#ajum00171-sec-0002}
====

A 21‐year‐old Caucasian G1P0 initially presented for evaluation of a one week history of significant chest pain and shortness of breath at 34 weeks gestational age. She was treated for pneumonia at an outside facility after a chest x‐ray revealed multiple pulmonary opacities. Her symptoms, however, failed to improve and she presented to our hospital for re‐evaluation.

Her pregnancy up to that point was uncomplicated. She was appropriately dated and her prenatal labs, including aneuploidy screening, were unremarkable. A second trimester ultrasound had confirmed normal fetal anatomy along with an unremarkable posterior placenta. On our evaluation, the patient was well appearing but reported persistent dull chest pain. She remained afebrile with an oxygen saturation of 96% on room air. Her pulmonary exam revealed mildly course breath sounds at the left apex. The reminder of the patient\'s examination was normal. A chest x‐ray was obtained, which showed over forty rounded opacities measuring 2--4 cm scattered throughout the lungs that appeared consistent with metastatic disease ([Figure 1](#ajum00171-fig-0001){ref-type="fig"}). Fetal wellbeing was assured with a non‐stress test. A quantitative hCG was drawn which exceeded 900,000 mIU/mL, and she was diagnosed with metastatic choriocarcinoma ([Figure 1](#ajum00171-fig-0001){ref-type="fig"}).
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Examination of the patient\'s vagina and CT scan of the brain, chest, abdomen, and pelvis revealed no additional sites of metastasis and was notable only for bilaterally enlarged ovaries with multiple thecal lutein cysts. A follow‐up growth ultrasound showed an appropriately growing fetus, with no obvious abnormalities or focal masses in the placenta.

The patient was diagnosed with stage III:11 choriocarcinoma based on WHO criteria. In consultation with the gynecologic oncology service, the decision was made to defer chemotherapy until after delivery with a cesarean selected as the planned route to allow evaluation of the ovaries and out of concern for possible hemorrhage following extraction of the placenta. Given her clinically stable condition, the patient opted for a period of conservative management. She was admitted to the hospital and monitored with daily non‐stress tests and twice‐weekly biophysical profiles (BPP) and MCA Dopplers with plans for scheduled delivery at 36 weeks EGA or sooner for signs of fetal or maternal compromise.

Her first BPP was obtained at a gestational age of 34 weeks and six days and reported as 8/10. MCA‐PSV Dopplers done at the time revealed a peak flow rate of 75--79 cm/sec which exceeded 1.5 multiples of the mean (MoM), 76.1 cm/sec at 35 weeks gestation,[^16^](#ajum00171-bib-0016){ref-type="ref"} and was consistent with fetal anemia thought to be secondary to hemorrhage at the placental site of the choriocarcinoma. ([Figure 2](#ajum00171-fig-0002){ref-type="fig"}). The patient underwent an exploratory laparotomy with primary low transverse cesarean delivery that day. Her surgery and post‐operative course were uncomplicated with an estimated blood loss of 700 mL. A small focal abnormality was noted on the placenta by the surgeons at the time of delivery; however, there was no evidence of retro‐placental clot. A post‐partum Kleihauer Betke test was obtained, which showed approximately 66 mL feto‐maternal hemorrhage. The patient received the appropriate dose of anti‐D immune globulin. Pathologic examination of the placenta revealed a 3.1 cm focus of choriocarcinoma, which was also confirmed on histology ([Figure 2](#ajum00171-fig-0002){ref-type="fig"}).
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Her female infant weighed 2270 g at delivery with 1 and 5 minute APGARs of 2 and 9 respectively and an arterial umbilical cord pH of 7.28. The infant was noted to have mild respiratory distress and was admitted to the NICU for a total of 22 days. Her admission hemoglobin was 12.3 g/dL and hematocrit 37.3% consistent with neonatal anemia (average hemoglobin is 16.5 g/dL and hematocrit is 65% at our facility), which responded to iron.

The patient was started on multiagent chemotherapy including etoposide, high‐dose methotrexate with folinic acid, actinomycin D, cyclophosphamide, and vincristine (EMA‐CO) for her high‐risk disease two weeks post‐partum. She required a total of five rounds of EMA‐CO to achieve an undetectable hCG level. Her chemotherapy course was complicated by severe neutropenia preceding cycle 2, which required a one‐week delay and mild peripheral neuropathy, which has since resolved. She is currently undergoing close surveillance and is disease free to date, thirteen months since delivery.

Discussion {#ajum00171-sec-0003}
==========

As previously described, the diagnosis of choriocarcinoma is generally made in the context of elevated quantitative hCG levels and radiologic evidence of metastatic disease. The presence of choriocarcinoma in a viable pregnancy is very rare and radiologic identification of the primary tumor is difficult given its usually small size. Identification of the placental lesion is possible in some cases with its sonographic appearance described as a hypervascular, heterogenous, and echogenic mass with areas of intralesional necrosis or hemorrhage[^18^](#ajum00171-bib-0018){ref-type="ref"} but was not evident in our patient\'s two ultrasounds. In general, radiographic identification of choriocarcinoma is possible, but technically difficult as grayscale appearance and Doppler ultrasound are nonspecific.[^19^](#ajum00171-bib-0019){ref-type="ref"} ^,^ [^20^](#ajum00171-bib-0020){ref-type="ref"} Accurate antepartum diagnosis depends on correlation with clinical findings and hCG levels.[^9^](#ajum00171-bib-0009){ref-type="ref"} CT scanning reveals the hypervascular metastatic lesions of choriocarcinoma well and is the most suitable method for evaluation of common metastatic sites.[^19^](#ajum00171-bib-0019){ref-type="ref"} MRI is usually reserved for equivocal cases or evaluation of brain or vaginal metastases[^9^](#ajum00171-bib-0009){ref-type="ref"} and was not performed in this case.

Reference values for MCA‐PSV were originally developed as a non‐invasive test for suspected neonatal anemia secondary to alloimmunisation and are correlated to umbilical cord hemoglobin at time of cordocentesis or delivery.[^16^](#ajum00171-bib-0016){ref-type="ref"} ^,^ [^21^](#ajum00171-bib-0021){ref-type="ref"} Conceptually, blood with lower hemoglobin values has increased velocity. In acute events, the hemoglobin level has not had time to equilibrate, therefore, when anemia is discovered in gestational choriocarcinoma by this method, it can be assumed the event is chronic. A chronic event, however, does not insinuate the need for expectant management as bleeding from choriocarcinoma can be sudden and catastrophic. Due to our patient\'s gestation and the presence of fetal anemia, the decision was made for delivery, although we recognise there are no standard guidelines.

This is the first case report to our knowledge of the use of Doppler ultrasonography to detect fetal anemia and guide delivery in a case of choriocarcinoma diagnosed during pregnancy. Although fetal anemia was detected on the first Doppler ultrasound prompting delivery, there exists the potential for this tool to be used to allow a pregnancy to progress safely. If gestational choriocarcinoma is detected antenatally, this may allow for a delay in delivery without fetal compromise in cases that have not yet developed feto‐maternal hemorrhage.
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